Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARTEMIS: A phase 2 trial of palupiprant (AN0025) with chemoradiotherapy and radiotherapy for the treatment of rectal cancer

Next Previous
X
Search
Trial Profile

ARTEMIS: A phase 2 trial of palupiprant (AN0025) with chemoradiotherapy and radiotherapy for the treatment of rectal cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palupiprant (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ARTEMIS

    • Most Recent Events

    • 23 May 2024 New trial record
    • 22 May 2024 According to an Adlai Nortye media release, study has been developed and is being led by the Cancer Research Clinical Trials Unit at the University of Leeds, with clinical leadership teams from consultant oncologists Prof Simon Gollins and Prof Mark Saunders.
    • 22 May 2024 According to an Adlai Nortye media release, company announced that the first patient was dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top